NOVO NORDISK A/S
Commented by André Will-Laudien on October 14th, 2025 | 07:20 CEST
CAUTION: Correction or even steeper rise? 100% with Planethic Group, Novo Nordisk, and Symrise
Does it always have to be "caviar"? As a luxury solution, this fish dish is deeply ingrained in the minds of many investors, but sometimes a smarter, hybrid-strategic mix may suffice. In the current market environment, the latest tariff policy from the White House feels like the flickering echo of a spy from Simmel's novel: unpredictable, tactical, and with far-reaching consequences. The threat of high tariffs on imports from numerous countries is putting supply chains on high alert and forcing companies to rethink their calculations. For investors, this means acting quickly, maintaining flexible portfolio weights, and questioning seemingly "safe" values. Those who favor local procurement channels are likely to navigate more stably. Here are a few ideas.
Read
Commented by Armin Schulz on October 9th, 2025 | 07:40 CEST
AI paves the way to the next blockbuster: The current situation at Novo Nordisk, NetraMark Holdings and Evotec
The pharmaceutical industry is at a historic turning point. Artificial intelligence is breaking through the lengthy and costly development cycles that have characterized the sector for decades. This technological quantum leap is revolutionizing drug discovery and promises to transform healthcare from the ground up. The first companies to master this AI revolution will be the biggest winners in a billion-dollar market. We therefore take a look at three companies that are already using AI today: the Danish pharmaceutical giant Novo Nordisk, AI specialist NetraMark Holdings for clinical studies, and the German research service provider Evotec, and analyze their current situation.
Read
Commented by Stefan Feulner on October 6th, 2025 | 07:05 CEST
Novo Nordisk, FuelCell Energy and Almonty Industries stage strong rebound
While many analysts are concerned about high valuations on the global stock markets, with the Warren Buffett indicator at a historic high, even exceeding its value before the dot-com bubble, the markets continue to rise from one high to the next. In fact, several companies staged a strong rebound last week, which is likely to pave the way for further gains by generating fresh buy signals.
Read
Commented by Carsten Mainitz on September 30th, 2025 | 07:40 CEST
Antimony Resources, Rheinmetall, Novo Nordisk – Something is in the air!
Sufficient access to raw materials is crucial for any economy. The EU has compiled a list of 34 critical raw materials. How critical a raw material is classified depends on two parameters: "economic importance" and "supply risk." This list also includes a little-known but very important metalloid – antimony. The price of antimony skyrocketed at the end of 2024 in the wake of China's export ban. There are still exciting investment opportunities in this area.
Read
Commented by Fabian Lorenz on September 29th, 2025 | 07:00 CEST
Takeover in the Ozempic market! BioNxt Solutions next? Novo Nordisk, Eli Lilly, and Pfizer are fighting!
The battle against obesity is considered one of the biggest growth markets in the global pharmaceutical sector. According to estimates, the market for obesity therapies could reach a volume of up to USD 150 billion by 2030. So far, Novo Nordisk and Eli Lilly have dominated the market. But almost every major corporation and innovative challenger wants a piece of the pie. The latest example: Pfizer is planning a billion-dollar takeover of US-based Metsera, a company competing with novel drugs against obesity. BioNxt Solutions is also a hot takeover candidate. The Company aims to revolutionize the market and attract new customers with an oral dosage form, and the first prototypes have already been developed. That makes it an attractive prospect for virtually every pharmaceutical company.
Read
Commented by Nico Popp on September 23rd, 2025 | 07:00 CEST
What MASH could do for your portfolio: BioNxt, Roche, Novo Nordisk
Have you heard of MASH? The acronym stands for metabolic-associated steatohepatitis, which was previously simply called "fatty liver." Medications targeting this disease, which studies suggest affects around 6% of Americans, are being hailed as the next big trend in the biotech market. Overall, one in three overweight individuals is affected. Since many patients initially show no symptoms, MASH is considered particularly insidious. The growing discussion around the condition could turn many at-risk individuals into patients who take medication, which is excellent news for certain companies in the sector. For a small-cap stock, the hype surrounding MASH could even be transformative.
Read
Commented by Armin Schulz on September 18th, 2025 | 07:15 CEST
Novo Nordisk, PanGenomic Health and Pfizer - Who are the winners of the digital health revolution?
The disruptive force of the digital health revolution is fundamentally changing the healthcare industry. Artificial intelligence, data-driven therapies, and digital diagnostics are opening up billion-dollar markets and catapulting agile players to the forefront. These pioneers are setting new standards in patient-centered care and generating exponential growth in the process. This ecosystem opens up unique opportunities for strategic investors. Today, we take a look at Novo Nordisk's restructuring, PanGenomic Health's AI-driven innovations, and the political uncertainties at Pfizer.
Read
Commented by Carsten Mainitz on September 17th, 2025 | 07:20 CEST
Globex Mining, Deutz, Novo Nordisk – Prices are rising!
On the stock market, there is often a difference between price and value. Companies with strong assets and holdings, or those with business models that benefit from long-term trends, tend to deliver attractive returns for investors in the long run. All the better if such companies can be acquired at a favorable price - one that lies below the fair value of their shares.
Read
Commented by Nico Popp on September 15th, 2025 | 07:15 CEST
No more diet injections! Innovations in weight loss drugs: BioNxt Solutions, Merck & Co., Novo Nordisk
As recently reported by the United Nations Children's Fund (UNICEF), for the first time, more children worldwide are obese than underweight. While this is a great success in the fight against hunger, it also poses new risks. Severe overweight in childhood leads to obesity and associated diseases in adulthood, such as cardiovascular problems and diabetes. The treatment of overweight and diabetes in children is therefore likely to play an even more significant role in the future. GLP-1 receptor agonists have been popular for several years now in the form of modern weight loss injections. With patents expiring soon, experts anticipate substantial further growth and development in this rapidly expanding market. We explain who could benefit and what the future holds for modern diet medications.
Read
Commented by Armin Schulz on September 12th, 2025 | 07:05 CEST
Investing in the future of medicine: A look at Novo Nordisk, NetraMark Holdings and Evotec
AI is completely transforming the pharmaceutical industry. Modern algorithms sift through vast amounts of data, identify promising therapeutic approaches, and advance drug development at record speed. This increase in efficiency is an absolute game changer. Not only does it save billions, but it also significantly increases success rates and catapults agile companies to the forefront. While cumbersome large corporations laboriously digitize their research departments, disruptive start-ups with innovative AI platforms are shaking up the market. It is precisely this dynamic that presents unique opportunities for investors, if they know how to decipher them. Today, we take a closer look at Danish pharmaceutical giant Novo Nordisk, AI specialist NetraMark Holdings, and German research service provider Evotec.
Read